Annuncio pubblicitario
Italia markets open in 6 hours 13 minutes

  • Dow Jones

    38.225,66
    +322,37 (+0,85%)
     

  • Nasdaq

    15.840,96
    +235,48 (+1,51%)
     

  • Nikkei 225

    38.236,07
    -37,98 (-0,10%)
     

  • EUR/USD

    1,0733
    +0,0006 (+0,05%)
     

  • Bitcoin EUR

    54.960,38
    +1.207,99 (+2,25%)
     

  • CMC Crypto 200

    1.270,69
    -0,05 (-0,00%)
     

  • HANG SENG

    18.207,13
    +444,10 (+2,50%)
     

  • S&P 500

    5.064,20
    +45,81 (+0,91%)
     

Immuneering to Present at the Morgan Stanley Healthcare Conference

Immuneering Corporation
·1 minuto per la lettura
Immuneering Corporation
Immuneering Corporation

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the Morgan Stanley Healthcare Conference to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Chief Accounting Officer and Treasurer.

Format: Fireside Chat and 1x1 Investor Meetings
Presentation: September 13, 2023 from 10:10 - 10:50 am ET

The presentations will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

ANNUNCIO PUBBLICITARIO

About Immuneering Corporation

Immuneering is a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. The company’s development pipeline also includes IMM-6-415, a universal-MAPK program, as well as several early-stage programs. For more information, please visit www.immuneering.com.

Media Contact:
Gina Nugent 
Nugent Communications 
617-460-3579 
gina@nugentcommunications.com

Investor Contacts: 
Laurence Watts 
Gilmartin Group 
619-916-7620 
laurence@gilmartinir.com

or

Kiki Patel, PharmD 
Gilmartin Group 
332-895-3225
kiki@gilmartinir.com